查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2084927

異位性皮膚炎治療市場：2026-2032年全球市場預測（按藥物類別、給藥途徑、給藥方法、患者年齡層、最終用戶和分銷管道分類）

Atopic Dermatitis Drugs Market by Drug Class, Route Of Administration, Mode Of Administration, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，異位性皮膚炎治療市場將成長至 309.9 億美元，複合年成長率為 9.11%。

主要市場統計數據
基準年 2025 168.2億美元
預計年份：2026年 183億美元
預測年份 2032 309.9億美元
複合年成長率 (%) 9.11%

異位性皮膚炎的治療正從控制症狀轉向針對慢性第2型發炎、搔癢、睡眠障礙、皮膚屏障功能受損和復發性加重等問題的標靶疾病修正治療。治療方案包括外用皮質類固醇、外用鈣調神經Calcineurin抑制劑、磷酸二酯酶-4抑制劑、外用Janus激酶（JAK）抑制劑、全身免疫抑制劑、生物製藥、以及重度疾病的口服JAK抑制劑。

這項需求源自於巨大的臨床負擔。經同行評審的皮膚病學文獻一致表明，在許多人群中，異位性皮膚炎影響高達約20%的兒童和高達約10%的成人，嚴重影響著患者的生活品質，包括搔癢、睡眠不足、焦慮、感染風險和生產力下降。隨著診斷率的提高、臨床指南的採納、保險公司監管力度的加強、兒童適應症的擴大，以及人們越來越傾向於選擇能夠快速緩解瘙癢並同時長期改善皮膚症狀且安全性高的治療方法，市場格局正在發生重塑。

異位性皮膚炎治療環境的變革性變化

異位性皮膚炎治療領域最顯著的轉變是從廣譜抗發炎療法轉向精準免疫療法。抑制白細胞介素-4和白細胞介素-13路徑已被確立為中度至重度異位性皮膚炎的第一線治療標準，而特異性白細胞介素-13的生物製藥療法則進一步完善了治療選擇。已獲已通過核准上市的口服JAK抑制劑能夠快速控制搔癢和皮損，但其黑框警告、實驗室監測、禁忌症和風險管理等要求，使得患者選擇和長期安全性監測顯得尤為重要。

人工智慧對異位性皮膚炎治療的累積影響

人工智慧正開始對異位性皮膚炎治療市場的各個階段產生影響，從藥物發現和開發到商業化和醫療服務。在藥物發現階段，人工智慧驅動的標靶識別和分子建模使開發人員能夠更有效率地評估細胞激素網路、JAK選擇性、皮膚屏障生物學特性、微生物組相互作用和搔癢路徑。在臨床開發階段，機器學習可用於輔助選擇研究中心、配對入合格、預測終點事件以及根據疾病嚴重程度、生物標記、合併症模式、既往治療史和潛在療效進行患者分層。

關於異位性皮膚炎治療的關鍵區域見解

北美地區仍然是異位性皮膚炎治療的重要區域，這得益於該地區專科醫生資源豐富、生物製藥供應充足、專科藥房基礎設施完善、私人保險覆蓋範圍廣，以及新藥獲批後迅速被廣泛採用。美國透過快速的市場推廣和廣泛的臨床試驗參與，推動了該地區的創新和需求成長；而加拿大則更注重報銷審查、臨床證據以及各省醫療保健系統內的公平醫療服務。

針對東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵群體特定見解

在東協市場，隨著都市區、私人醫院網路、皮膚病學意識以及對過敏相關疾病的認知不斷提高，生物製藥的重要性日益凸顯。然而，新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國的生物製藥服務可近性仍有差異。海灣合作理事會（GCC）國家憑藉其專業的醫療基礎設施、國家醫療保健投資、政府支持的醫療模式以及在三級醫療機構中對創新品牌藥物的偏好，有望加速生物製藥和先進療法的應用。

各國異位性皮膚炎治療的關鍵見解

美國是異位性皮膚炎治療藥物的主要商業市場，這得益於其完善的FDA核准流程、專業的藥房基礎設施、較高的患者意識、生物製藥的高使用率以及對靶向口服和外用藥物創新療法的強勁需求。加拿大正在採用更注重實證醫學和醫療保險主導的模式，而墨西哥儘管高度依賴傳統外用療法，但民營市場對先進療法的使用率正在不斷提高。巴西在皮膚病學領域的規模和生物製藥的可及性方面領先於拉丁美洲，但公共醫療保險報銷、治療費用以及醫療保健方面的區域差異仍然是決定性因素。

為行業領導者提供的實用建議

產業領導者應優先考慮差異化的臨床價值，而不僅僅是作用機制的新穎性。最大的機會在於那些能夠快速緩解搔癢、持續控制濕疹、長期安全使用、適用於兒童、減少類固醇用量、降低復發率，以及對臉部、手部、眼瞼和易摩擦皮膚等難治部位有效的療法。

調查方法

本執行摘要採用結構化的二級研究途徑編寫，符合醫藥市場情報標準。分析整合了公開的監管資訊、皮膚病學指南、同行評審的臨床文獻、現有產品附加檔、衛生技術評估趨勢、臨床試驗註冊資訊、藥物安全監測注意事項以及公認的流行病學資訊來源，內容涉及異位性皮膚炎的盛行率、嚴重程度、合併症和治療途徑。

結論

異位性皮膚炎治療市場競爭日益激烈，且越來越注重實證醫學。標靶生物製藥、口服JAK抑制劑和先進的局部療法正在拓展治療選擇，使其不再局限於傳統的局部皮質類固醇和全身性免疫抑制劑。同時，安全性、可近性、依從性和成本效益仍然是影響處方決策的重要因素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 異位性皮膚炎治療市場：依藥物類別分類

  • 全身
    • 生物製劑
    • 低分子量免疫抑制劑
  • 外用藥物
    • Calcineurin抑制劑
    • 皮質類固醇
    • PDE4抑制劑
    • 維生素D類似物

第8章：異位性皮膚炎治療市場：依給藥途徑分類

  • 奶油
  • 凝膠
  • 洗劑
  • 軟膏

第9章 異位性皮膚炎治療市場：依給藥途徑分類

  • 注射藥物
    • 預填充式注射器
    • 管瓶
  • 口服

第10章 異位性皮膚炎治療市場：依患者年齡層分類

  • 成人
  • 老年人
  • 兒童

第11章 異位性皮膚炎治療市場：依最終用戶分類

  • 醫院
  • 皮膚科診所
  • 居家照護

第12章 異位性皮膚炎治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
    • 數位健康平台
    • 電子商務平台
  • 零售藥房

第13章 異位性皮膚炎治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 異位性皮膚炎治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 異位性皮膚炎治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Arcutis Biotherapeutics, Inc.
  • AstraZeneca PLC
  • Avanti's Skin and Laser Clinic
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biofrontera AG
  • Bristol-Myers Squibb Company
  • Chugai Pharmaceutical Co., Ltd.
  • Daavlin Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Galderma Holding SA
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Johnson & Johnson Services Inc.
  • LEO Pharma A/S
  • Maruho Co., Ltd
  • Novartis AG
  • Organon & Co.
  • Otsuka Pharmaceutical Co., Ltd.
  • Perrigo Company PLC
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc
  • Sanofi SA
  • Solarc Systems Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Torii Pharmaceutical Co., Ltd.
  • UCB SA
  • Viatris Inc.
Product Code: MRR-436901065D12

The Atopic Dermatitis Drugs Market is projected to grow by USD 30.99 billion at a CAGR of 9.11% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.82 billion
Estimated Year [2026] USD 18.30 billion
Forecast Year [2032] USD 30.99 billion
CAGR (%) 9.11%

Atopic dermatitis drugs are moving from symptom control toward targeted, disease-modifying management of chronic type 2 inflammation, itch, sleep disruption, skin barrier dysfunction, and recurrent flares. The treatment landscape spans topical corticosteroids, topical calcineurin inhibitors, phosphodiesterase-4 inhibitors, topical Janus kinase (JAK) inhibitors, systemic immunosuppressants, biologics, and oral JAK inhibitors used in moderate-to-severe disease.

Demand is supported by a large clinical burden: peer-reviewed dermatology literature consistently reports that atopic dermatitis affects up to about 20% of children and up to about 10% of adults in many populations, with meaningful quality-of-life impact related to pruritus, sleep loss, anxiety, infection risk, and productivity impairment. The market is being reshaped by higher diagnosis rates, guideline adoption, payer scrutiny, pediatric label expansions, and the growing expectation that therapies should reduce itch rapidly while sustaining long-term skin clearance and safety.

Transformative Shifts in the Atopic Dermatitis Treatment Landscape

The most important shift in the atopic dermatitis drugs landscape is the move from broad anti-inflammatory treatment to precision immunology. Interleukin-4 and interleukin-13 pathway inhibition has established a major standard for moderate-to-severe disease, while interleukin-13-specific targeting has further refined biologic treatment options. Oral JAK inhibitors in approved markets have added rapid itch and lesion control, but boxed warnings, laboratory monitoring, contraindications, and risk management requirements have sharpened the importance of patient selection and long-term safety surveillance.

Topical innovation is also changing treatment sequencing. Nonsteroidal options such as phosphodiesterase-4 inhibition and topical JAK inhibition address steroid-sparing needs, while newer formulations seek better tolerability, adherence, and use in sensitive body areas. As payers compare acquisition cost, durability, safety, and real-world outcomes, manufacturers are increasingly required to demonstrate value through comparative evidence, patient-reported outcomes, flare reduction, sleep improvement, and reduced healthcare utilization.

Cumulative Impact of Artificial Intelligence on Atopic Dermatitis Drugs

Artificial intelligence is beginning to influence the atopic dermatitis drugs market across discovery, development, commercialization, and care delivery. In drug discovery, AI-enabled target identification and molecular modeling are helping developers evaluate cytokine networks, JAK selectivity, skin-barrier biology, microbiome interactions, and itch pathways more efficiently. In clinical development, machine learning can support trial site selection, eligibility matching, endpoint prediction, and stratification of patients by disease severity, biomarkers, comorbidity patterns, prior treatment exposure, and likelihood of response.

The cumulative impact is expected to be strongest in real-world evidence generation and personalized treatment pathways. AI-assisted image analysis can standardize lesion severity assessments, while digital tools can track flares, sleep loss, itch intensity, adherence, treatment response, and adverse events between visits. For industry leaders, the opportunity is not simply automation; it is building evidence ecosystems that connect dermatology workflows, patient-reported outcomes, pharmacovigilance, health economics, and payer-relevant value metrics.

Key Regional Insights for Atopic Dermatitis Drugs

North America remains a high-value region for atopic dermatitis drugs because of specialist access, biologic adoption, specialty pharmacy infrastructure, commercial insurance coverage, and strong uptake of new mechanisms after regulatory approval. The United States drives much of the regional innovation and demand through rapid launch activity and broad clinical trial participation, while Canada emphasizes reimbursement review, clinical evidence, and equitable access across provincial systems.

Europe is characterized by mature dermatology guidelines, centralized regulatory evaluation, national health technology assessment processes, and careful cost-effectiveness review for biologics, oral JAK inhibitors, and advanced topical therapies. Asia-Pacific is expanding as China, Japan, South Korea, India, Australia, and ASEAN markets address rising diagnosis, urbanization-linked allergic disease burden, expanding specialty care, and broader access to immunology-based treatment. Latin America, led by Brazil and Mexico, shows growing demand for advanced eczema therapies but faces affordability, reimbursement, and public-sector access constraints. The Middle East, especially GCC markets, benefits from high healthcare investment, tertiary specialist centers, and premium therapy adoption, while Africa remains underpenetrated due to limited specialist density, diagnostic gaps, access constraints, and continued reliance on essential topical therapies.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are becoming increasingly relevant as urban populations, private hospital networks, dermatology awareness, and allergy-related disease recognition expand, although access remains uneven across Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. GCC countries are positioned for faster adoption of biologics and advanced therapies due to specialist infrastructure, national health investments, government-backed care models, and a preference for innovative branded medicines in tertiary care.

The European Union is a critical evidence-led market where regulatory approval, pharmacoeconomic review, prescribing guidance, and post-marketing data strongly shape adoption. BRICS countries represent scale and long-term demand, led by China, India, and Brazil, but pricing, reimbursement, local evidence generation, and manufacturing strategies are central to success. G7 markets continue to set the benchmark for clinical standards, regulatory rigor, premium access evidence, and launch sequencing. NATO countries, while not a healthcare bloc, overlap with many high-income markets where medicine security, supply resilience, pharmacovigilance coordination, and regulatory alignment increasingly influence pharmaceutical strategy.

Key Country Insights for Atopic Dermatitis Drugs

The United States is the central commercialization market for atopic dermatitis drugs, supported by FDA pathways, specialty pharmacy infrastructure, patient awareness, high biologic utilization, and strong demand for targeted oral and topical innovation. Canada follows a more evidence- and reimbursement-driven model, while Mexico shows growing private-market use of advanced therapies alongside broader reliance on conventional topical treatments. Brazil leads Latin America in dermatology scale and biologic access, although public reimbursement, affordability, and regional care variation remain decisive.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine robust dermatology expertise with payer scrutiny, making comparative effectiveness, guideline alignment, and real-world outcomes essential. Russia has demand for dermatology therapies but faces access, reimbursement, and supply-chain complexity. China is rapidly expanding as regulatory modernization, local innovation, and specialty care improve, while India offers large patient volume but remains highly price-sensitive with significant use of topical and generic therapies. Japan has strong dermatology standards and early adoption of selected advanced therapies, Australia benefits from structured reimbursement and specialist access, and South Korea combines advanced healthcare infrastructure with growing demand for targeted immunology treatments.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical value rather than mechanism novelty alone. The strongest opportunities lie in therapies that demonstrate rapid itch relief, durable eczema control, safe long-term use, pediatric utility, steroid-sparing benefits, lower flare frequency, and performance in difficult-to-treat areas such as the face, hands, eyelids, and intertriginous skin.

Organizations should invest in real-world evidence, payer-aligned outcomes, and digital adherence programs that document reduced flares, fewer physician visits, improved sleep, better quality of life, and lower corticosteroid burden. Market access strategies should be tailored by region: premium evidence packages for the United States, G7, and EU; affordability, local evidence, and partnership models for BRICS and Latin America; and specialist education plus formulary engagement in ASEAN, GCC, Middle Eastern, and emerging African markets.

Research Methodology

This executive summary is developed using a structured secondary research approach aligned with pharmaceutical market intelligence standards. The analysis synthesizes publicly available regulatory information, dermatology guidelines, peer-reviewed clinical literature, product labels where available, health technology assessment patterns, clinical trial registries, pharmacovigilance considerations, and recognized epidemiology sources for atopic dermatitis prevalence, severity, comorbidities, and treatment pathways.

Insights are validated through triangulation across clinical, commercial, and policy dimensions, including mechanism-of-action trends, regional access conditions, reimbursement dynamics, competitive positioning, patient-reported outcomes, safety requirements, and real-world evidence needs. The methodology emphasizes verified, data-backed interpretation and avoids unsupported market sizing, market share, or forecasting where consistent public estimates are not available.

Conclusion

The atopic dermatitis drugs market is entering a more competitive and evidence-intensive phase. Targeted biologics, oral JAK inhibitors, and advanced topical therapies are expanding treatment possibilities beyond conventional topical corticosteroids and systemic immunosuppressants, while safety, access, adherence, and cost-effectiveness continue to shape prescribing decisions.

Future leadership will depend on integrated strategies that combine clinical differentiation, patient-centric outcomes, AI-enabled evidence generation, and region-specific market access execution. Developers that can prove durable disease control, improve quality of life, support safe long-term use, and address affordability across diverse health systems will be best positioned in the global atopic dermatitis therapeutics landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Atopic Dermatitis Drugs Market, by Drug Class

  • 7.1. Systemic
    • 7.1.1. Biologics
    • 7.1.2. Small Molecule Immunosuppressants
  • 7.2. Topical
    • 7.2.1. Calcineurin Inhibitors
    • 7.2.2. Corticosteroids
    • 7.2.3. PDE4 Inhibitors
    • 7.2.4. Vitamin D Analogues

8. Atopic Dermatitis Drugs Market, by Route Of Administration

  • 8.1. Cream
  • 8.2. Gel
  • 8.3. Lotion
  • 8.4. Ointment

9. Atopic Dermatitis Drugs Market, by Mode Of Administration

  • 9.1. Injectable
    • 9.1.1. Pre Filled Syringes
    • 9.1.2. Vials
  • 9.2. Oral

10. Atopic Dermatitis Drugs Market, by Patient Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Atopic Dermatitis Drugs Market, by End User

  • 11.1. Hospitals
  • 11.2. Dermatology Clinics
  • 11.3. Homecare

12. Atopic Dermatitis Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
    • 12.2.1. Digital Health Platforms
    • 12.2.2. E Commerce Platforms
  • 12.3. Retail Pharmacies

13. Atopic Dermatitis Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Atopic Dermatitis Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Atopic Dermatitis Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Amgen Inc.
  • 17.3. Arcutis Biotherapeutics, Inc.
  • 17.4. AstraZeneca PLC
  • 17.5. Avanti's Skin and Laser Clinic
  • 17.6. Bausch Health Companies Inc.
  • 17.7. Bayer AG
  • 17.8. Biofrontera AG
  • 17.9. Bristol-Myers Squibb Company
  • 17.10. Chugai Pharmaceutical Co., Ltd.
  • 17.11. Daavlin Company
  • 17.12. Eli Lilly and Company
  • 17.13. F. Hoffmann-La Roche Ltd.
  • 17.14. Galderma Holding SA
  • 17.15. GlaxoSmithKline PLC
  • 17.16. Incyte Corporation
  • 17.17. Johnson & Johnson Services Inc.
  • 17.18. LEO Pharma A/S
  • 17.19. Maruho Co., Ltd
  • 17.20. Novartis AG
  • 17.21. Organon & Co.
  • 17.22. Otsuka Pharmaceutical Co., Ltd.
  • 17.23. Perrigo Company PLC
  • 17.24. Pfizer, Inc.
  • 17.25. Regeneron Pharmaceuticals, Inc
  • 17.26. Sanofi SA
  • 17.27. Solarc Systems Inc.
  • 17.28. Teva Pharmaceutical Industries Ltd.
  • 17.29. Torii Pharmaceutical Co., Ltd.
  • 17.30. UCB S.A.
  • 17.31. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ATOPIC DERMATITIS DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ATOPIC DERMATITIS DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ATOPIC DERMATITIS DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ATOPIC DERMATITIS DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ATOPIC DERMATITIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SYSTEMIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SYSTEMIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SYSTEMIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SMALL MOLECULE IMMUNOSUPPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SMALL MOLECULE IMMUNOSUPPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SMALL MOLECULE IMMUNOSUPPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VITAMIN D ANALOGUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VITAMIN D ANALOGUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VITAMIN D ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CREAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CREAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CREAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LOTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LOTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LOTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OINTMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OINTMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PRE FILLED SYRINGES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PRE FILLED SYRINGES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PRE FILLED SYRINGES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DERMATOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DERMATOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DERMATOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIGITAL HEALTH PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIGITAL HEALTH PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIGITAL HEALTH PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL E COMMERCE PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL E COMMERCE PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL E COMMERCE PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 168. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 201. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 203. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 204. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 205. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 208. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 212. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 215. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 216. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 235. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 237. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 238. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 239. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 242. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 246. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 248. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 249. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 250. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 257. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 260. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 261. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 264. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 279. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 281. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 282. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 283. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 284. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 286. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 290. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 292. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 293. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 294. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 295. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 301. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 303. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 304. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 305. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 308. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 309. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 312. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 313. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 314. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 315. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 316. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 318. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 319. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 320. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 322. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 323. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 325. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 326. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 327. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 328. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 329. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 330. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 331. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 332. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 333. SPAIN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 339. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 340. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 342. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 343. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 344. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 345. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 346. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 347. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 348. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 349. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 350. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 351. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 352. INDIA